Evelo Biosciences, Inc. (EVLO) News

Evelo Biosciences, Inc. (EVLO): $2.75

0.01 (+0.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EVLO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter EVLO News Items

EVLO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

EVLO News Highlights

  • For EVLO, its 30 day story count is now at 10.
  • Over the past 17 days, the trend for EVLO's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • APLS, BEAT and BMO are the most mentioned tickers in articles about EVLO.

Latest EVLO News From Around the Web

Below are the latest news stories about Evelo Biosciences Inc that investors may wish to consider to help them evaluate EVLO as an investment opportunity.

5 Drug/Biotech Stocks Set to Outpace Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks, EVLO, GMDA, APLS, MRTX and ITOS, which are poised to beat on fourth-quarter earnings.

Yahoo | February 24, 2022

Evelo Biosciences begins dosing in phase 2 trial of EDP1815 for eczema

Evelo Biosciences (EVLO) said the first patient was dosed in a phase 2 trial of EDP1815 to treat patients with mild, moderate, and severe atopic dermatitis, also known…

Seeking Alpha | February 17, 2022

Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis

CAMBRIDGE, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that the first patient has been dosed in EDP1815-207, its Phase 2 randomized clinical trial of EDP1815 for the treatment of patients with mild, moderate, and severe atopic dermatitis. “We are pleased that dosing has begun in the Phase 2 trial to eval

Yahoo | February 17, 2022

INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors.

Yahoo | February 15, 2022

Evelo Biosciences, Inc. (EVLO) Upgraded to Buy: Here's What You Should Know

Evelo Biosciences, Inc. (EVLO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | February 11, 2022

BMO Capital Thinks Evelo Biosciences’ Stock is Going to Recover

In a report released today, Gary Nachman from BMO Capital maintained a Buy rating on Evelo Biosciences (EVLO – Research Report), with a price target of $23.00. The company's shares closed last Tuesday at $4.45, close to its 52-week low of $4.20. According to TipRanks.com, Nachman is ranked 0 out of 5 stars with an average return of -5.3% and a 40.8% success rate. Nachman covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Horizon Therapeutics, and Jazz Pharmaceuticals. Evelo Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $17.50, representing a 297.7% upside. In a report released yesterday, Cowen & Co.

Christine Brown on TipRanks | February 8, 2022

Evelo Biosciences posts biomarker data from Phase 2 psoriasis study

Reporting data from a biomarker analysis of its Phase 2 trial for EDP1815 in patients with psoriasis, Evelo Biosciences (NASDAQ:EVLO) said that there was a statistically significant reduction in the release of pro-inflammatory cytokines following the oral treatment. The blood samples of 96 patients were analyzed after the treatment with...

Seeking Alpha | February 7, 2022

Evelo Biosciences'' Psoriasis Candidate Shows Reductions In Inflammatory Cytokines

Evelo Biosciences Inc (NASDAQ: EVLO ) has announced the results of immunological biomarker analyses from its previously reported Phase 2 trial of orally-dosed EDP1815 in mild and moderate psoriasis. Treatment with EDP1815 led to a statistically significant reduction in the release of cytokines compared to placebo : IL-6 (p=0.0003), IL-8 (p=0.0007), and TNF (p=0.0037). The effect of EDP1815 was observed by … Full story available on Benzinga.com

Benzinga | February 7, 2022

Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in EDP1815 Phase 2 Psoriasis Trial

EDP1815 led to significantly lower production of IL-6, IL-8 and TNF Data announced by Evelo on February 7, 2022 PASI-50+ responders showed reduced levels of cytokine RNA in psoriatic skin after 16 weeks of treatment with EDP1815 Data announced by Evelo on February 7, 2022 Treatment with EDP1815 led to reduced production of cytokines IL-6, IL-8, and TNF in blood cellsCytokine analysis supports gut-restricted action of EDP1815 to resolve inflammation throughout the bodyReductions in IL-12b, IL-17,

Yahoo | February 7, 2022

Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases

CAMBRIDGE, Mass., Jan. 17, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (NASDAQ: EVLO ), a clinical stage biotechnology company developing SINTAX medicines as a new modality of orally delivered treatments for inflammatory disease, today announced data for EDP1815, the Company''s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis. The data were presented in two posters on Saturday, January 15, 2022, at the 2022 Winter Clinical Dermatology Congress in Koloa, Hawaii. "The data presented today build on the substantial evidence accumulated through our clinical and preclinical work, deepening our understanding of the mechanism by which EDP1815 drives its clinical effects. They explain...

Benzinga | January 17, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.1579 seconds.